Immunome (IMNM) Gains from Investment Securities (2019 - 2026)
Immunome (IMNM) reported Gains from Investment Securities of $500000.0 for Q1 2026, up 123.21% on a YoY basis from $224000.0 in Q1 2025, and up 400.0% quarter-over-quarter from $100000.0 in Q4 2025.
Immunome (IMNM) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Immunome has reported Gains from Investment Securities for 8 years, with the latest figure at $500000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 123.21% year-over-year to $500000.0; the trailing twelve-month figure through Mar 2026 stood at $500000.0 (up 123.21% YoY), and the FY2025 full-year result was $1.1 million, down 25.88% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $500000.0, up from $100000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $8.5 million in Q2 2024, with the low at -$6.9 million in Q4 2024.
- Historically, Gains from Investment Securities has averaged $792570.6 across 5 years, with a median of $422169.5 in 2024.
- The largest YoY upside for Gains from Investment Securities was 8593.08% in 2024 against a maximum downside of 664.16% in 2024.
- Immunome's Gains from Investment Securities stood at -$15000.0 in 2022, then jumped by 8266.67% to $1.2 million in 2023, then plunged by 664.16% to -$6.9 million in 2024, then soared by 101.45% to $100000.0 in 2025, then soared by 400.0% to $500000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $500000.0 (Q1 2026), $100000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Immunome | 2.12 Bn | 1.54 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 1.06 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 902,684.00 |
| Jun 30, 2025 | 902,684.00 |
| Mar 31, 2025 | 224,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | -6.91 Mn |
| Dec 31, 2024 | -6.91 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 8.54 Mn |
| Jun 30, 2024 | 8.54 Mn |
| Mar 31, 2024 | 344,339.00 |
| Mar 31, 2024 | 344,339.00 |
| Dec 31, 2023 | 1.23 Mn |
| Dec 31, 2023 | 1.23 Mn |